Evolving Clinical Paradigms for LDL Lowering: Focus on Efficacy, Implications, Side Effects, and Safety Results of Landmark Trials Evaluating PCSK9 Inhibition, APOB Suppression, and Other Novel Targets—Implications for the Diabetic Patient - James M. McKenney, PharmD